Country: Canada
Language: English
Source: Health Canada
MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE)
ANGITA PHARMA INC.
J01MA14
MOXIFLOXACIN
400MG
TABLET
MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) 400MG
ORAL
30
Prescription
QUINOLONES
Active ingredient group (AIG) number: 0142242001; AHFS:
APPROVED
2018-06-28
_AG-_ _MOXIFLOXACIN _ _Page 1 of 70 _ PRODUCT MONOGRAPH PR AG - MOXIFLOXACIN Moxifloxacin Tablets 400 mg (as moxifloxacin hydrochloride) Antibacterial Agent Date of Revision: August 03, 2022 Manufactured by: Angita Pharma Inc. 1310 rue Nobel Boucherville,Québec J4B 5H3 Canada SUBMISSION CONTROL NO: 265857 _AG-_ _MOXIFLOXACIN _ _Page 2 of 70 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ........................................................... 3 SUMMARY PRODUCT INFORMATION ......................................................................... 3 INDICATIONS AND CLINICAL USE ................................................................................ 3 CONTRAINDICATIONS .................................................................................................... 5 WARNINGS AND PRECAUTIONS ................................................................................... 6 ADVERSE REACTIONS .................................................................................................. 14 DRUG INTERACTIONS ................................................................................................... 18 DOSAGE AND ADMINISTRATION ............................................................................... 20 OVERDOSAGE ................................................................................................................. 21 ACTION AND CLINICAL PHARMACOLOGY .............................................................. 22 STORAGE AND STABILITY ........................................................................................... 29 SPECIAL HANDLING INSTRUCTIONS ......................................................................... 30 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................. 31 PART II: SCIENTIFIC INFORMATION ................................................................................. 32 PHARMACEUTICAL INFORMATION ............................................................................ 32 CLINICAL TRIALS ... Read the complete document